Key facts
- It has raised $1.0M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Mar 2025.
- Notable investors include C10 Labs, Future Labs Capital.
- DeepkinetiX has filed 1 Form D with the SEC, most recently Mar 2025 ($1.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for DeepkinetiX
Funding rounds
1 roundsAbout DeepkinetiX
Developer of an AI-driven model-informed software designed to optimize pharmaceutical drug development. The company's platform utilizes model-informed drug development and AI-driven predictive insights, simulating and predicting drug behavior to reduce research and development costs and time, enabling pharmaceutical companies, hospitals, contract research organizations, drug development companies, and biotech startups to gain insights into drug pharmacokinetics and pharmacodynamics, predict clinical trial outcomes, and accelerate the drug development process.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 10
- Website
- deepkinetix.com/
- Ownership
- Privately Held (backing)
DeepkinetiX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepkinetiX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepkinetiX in its N-PORT filings yet. We sweep new filings monthly.